ResearcherOslo University HospitalActive in the last 2 years
Olav Faisal Dajani
Matched on ORCID iD 0000-0002-9115-8529; OpenAlex author ID A5017669406. Sources: ClinicalTrials.gov.
Their work
- Papers
- 5
- Trials
- 1 (principal investigator on 1)
- Grants
- 0
- Labs led
- 0
- Collaborators
- 46
2015: 1 paper · 2016: none · 2017: 1 trial · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 4 papers
Papers 5
- Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert survey and case vignette study. Co-author DOI 10.1016/j.ejso.2024.109544↗
- Study protocol of the METAPANC trial - intensified treatment in patients with local operable but oligometastatic pancreatic cancer - multimodal surgical treatm… Co-author DOI 10.1186/s12885-025-13573-7↗
- Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Surviva… Co-author DOI 10.1200/jco-25-01631↗
- Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cac… Co-author DOI 10.1200/jco.23.01965↗
- Comparing two classifications of cancer cachexia and their association with survival in patients with unresected pancreatic cancer. Co-author DOI 10.1080/01635581.2015.1004728↗
Trials 1
Closest collaborators
The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Katherine R. Pelz · 2 shared papers, 2025 · strength 0.41
- Paper Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatmen… DOI 10.1200/jco-25-01631↗
- Paper Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Adva… DOI 10.1200/jco.23.01965↗
- Susann Theile · 2 shared papers, 2025 · strength 0.41
- Paper Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatmen… DOI 10.1200/jco-25-01631↗
- Paper Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Adva… DOI 10.1200/jco.23.01965↗
- Denis C. Guttridge D · 2 shared papers, 2025 · strength 0.41
- Paper Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatmen… DOI 10.1200/jco-25-01631↗
- Paper Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Adva… DOI 10.1200/jco.23.01965↗
- Dorte Lisbet Nielsen · 2 shared papers, 2025 · strength 0.41
- Paper Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatmen… DOI 10.1200/jco-25-01631↗
- Paper Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Adva… DOI 10.1200/jco.23.01965↗
- Julia Sidenius Johansen · 2 shared papers, 2025 · strength 0.41
- Paper Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatmen… DOI 10.1200/jco-25-01631↗
- Paper Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Adva… DOI 10.1200/jco.23.01965↗
- Teresa A Zimmers · 2 shared papers, 2025 · strength 0.41
- Paper Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatmen… DOI 10.1200/jco-25-01631↗
- Paper Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Adva… DOI 10.1200/jco.23.01965↗
- Inna Markovna Chen · 2 shared papers, 2025 · strength 0.41
- Paper Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatmen… DOI 10.1200/jco-25-01631↗
- Paper Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Adva… DOI 10.1200/jco.23.01965↗
- Michael C. Ostrowski · 2 shared papers, 2025 · strength 0.41
- Paper Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatmen… DOI 10.1200/jco-25-01631↗
- Paper Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Adva… DOI 10.1200/jco.23.01965↗
- Marc G. Besselink · 2 shared papers, 2025 · strength 0.35
- Paper Study protocol of the METAPANC trial - intensified treatment in patients with local operable but oligometastatic pancre… DOI 10.1186/s12885-025-13573-7↗
- Paper Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert s… DOI 10.1016/j.ejso.2024.109544↗
- Inna Chen · 1 shared trial, 2017 · strength 0.22
- Hanneke W. Wilmink · 1 shared paper, 2025 · strength 0.19
- Svein Olav Bratlie · 1 shared paper, 2025 · strength 0.19
- Michael B. Ghadimi · 1 shared paper, 2025 · strength 0.19
- Peter Jo · 1 shared paper, 2025 · strength 0.19
- Hanna E. Seppänen · 1 shared paper, 2025 · strength 0.19
- Bas A. Uijterwijk · 1 shared paper, 2025 · strength 0.19
- Pauli Antero Puolakkainen · 1 shared paper, 2025 · strength 0.19
- Jens Thomas Siveke · 1 shared paper, 2025 · strength 0.19
- Uwe Pelzer · 1 shared paper, 2025 · strength 0.19
- Alexander Otto König · 1 shared paper, 2025 · strength 0.19
- Knut Jørgen Labori · 1 shared paper, 2025 · strength 0.19
- Rickmer Braren · 1 shared paper, 2025 · strength 0.19
- Robert C. Verdonk · 1 shared paper, 2025 · strength 0.16
- Lois A. Daamen · 1 shared paper, 2025 · strength 0.16
- Izaak Quintus Molenaar · 1 shared paper, 2025 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.